<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INTERFERON ALFA-2b</span><br/>(in-ter-feer'on)<br/><span class="topboxtradename">Intron A<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span>; <span class="classification">interferon</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 million IU, 10 million IU, 18 million IU, 25 million IU, 50 million IU vials</p>
<h1><a name="action">Actions</a></h1>
<p>Alpha (leukocyte) interferon is a natural product induced virally in peripheral WBC or lymphoblastoid cells. The drug interferon
         alfa-2b is obtained by recombinant DNA technology from a strain of <i>Escherichia coli</i> bearing an interferon alfa-2b gene from human leukocytes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has the same actions (antiviral, immunomodulating, antiproliferative) as interferon alfa-2a.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hairy cell leukemia in splenectomized and nonsplenectomized patients <img src="../images/special/greaterorequal.gif"/>18 y,
         chronic hepatitis B or C.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Multiple sclerosis, condylomata acuminata, AIDS-related Kaposi's sarcoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to interferon alfa-2b or to any components of the product. Safe use during pregnancy (category C), lactation,
         or children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Severe, preexisting cardiac, renal, or hepatic disease; pulmonary disease (e.g., COPD); diabetes mellitus patients prone to
         ketoacidosis; coagulation disorders; severe myelosuppression; recent MI; previous dysrhythmias.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hairy Cell Leukemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 2 million U/m<sup>2</sup> 3 times/wk<br/><br/><span class="indicationtitle">Kaposi's Sarcoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 30 million U/m<sup>2</sup> 3 times/wk<br/><br/><span class="indicationtitle">Condylomata Acuminata</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/SC</span> 1 million U/m<sup>2</sup> 3 times/wk<br/><br/><span class="indicationtitle">Chronic Hepatitis B or C</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 3 million U 3 times/wk x 1824 mo<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Interferon alfa-2b should be administered under the guidance of a qualified physician.
         		
      </p><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitution: The final concentration with the amount of required diluent is determined by the condition being treated (see
            manufacturer's directions). Inject diluent (bacteriostatic water for injection) into interferon alfa-2b vial; gently agitate
            solution before withdrawing dose with a sterile syringe.
         </li>
<li>Make sure reconstituted solution is clear and colorless to light yellow and free of particulate material; discard if there
            are particles or solution is discolored.
         </li>
<li>Store vials and reconstituted solutions at 2°8° C (36°46° F); remains stable for 1 mo.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Flu-like syndrome (fever, chills) associated with myalgia and arthralgia,</span> leg cramps. <span class="typehead">CNS:</span> Depression, nervousness, anxiety, confusion, <span class="speceff-common">dizziness, fatigue,</span> somnolence, insomnia, altered mental states, ataxia, tremor, paresthesias, <span class="speceff-common">headache</span>. <span class="typehead">CV:</span> Hypertension, dyspnea, <span class="speceff-common">hot flushes</span>. <span class="typehead">Special Senses:</span> Epistaxis, pharyngitis, sneezing; abnormal vision. <span class="typehead">GI:</span> Taste alteration, <span class="speceff-common">anorexia,</span> weight loss, <span class="speceff-common">nausea,</span> vomiting, stomatitis, <span class="speceff-common">diarrhea,</span> flatulence. <span class="typehead">Hematologic:</span> Mild thrombocytopenia, transient granulocytopenia, <span class="speceff-common">anemia</span>, <span class="speceff-both">neutropenia</span>, <span class="speceff-life">leukemia</span>. <span class="typehead">Skin:</span> Mild pruritus, mild alopecia, rash, dry skin, herpetic eruptions, nonherpetic cold sores, urticaria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>theophylline</b> levels; additive myelosuppression with <span class="classification">antineoplastics</span>, <b>zidovudine</b> may increase hematologic toxicity, increase <b>doxorubicin</b> toxicity, increase neurotoxicity with <b>vinblastine.</b> Use with <b>ribavirin</b> increases risk of hemolytic anemia; do not use in combination with <b>ribavarin</b> if Cr<sub>Cl</sub> <a name="pharmaks">Pharmacokinetics</a><span class="typehead">Peak:</span> 68 h. <span class="typehead">Metabolism:</span> Metabolized in kidneys. <span class="typehead">Half-Life:</span> 67 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p>(see <small>INTERFERON ALFA-2A</small>)
      </p>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess hydration status; patient should be well hydrated, especially during initial stage of treatment and if vomiting or
            diarrhea occurs.
         </li>
<li>Lab tests: Closely monitor CBC with differential and platelet counts.</li>
<li>Monitor for ecchymoses, petechiae, and bruising.</li>
<li>Assess for flu-like symptoms, which may be relieved by acetaminophen (if prescribed).</li>
<li>Monitor level of GI distress and ability to consume fluids and food.</li>
<li>Monitor mental status and alertness; implement safety precautions if needed.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn techniques for reconstitution and administration of drug.</li>
<li>Do <small>NOT</small> change brands of interferon without first consulting the physician.
         </li>
<li>
            							Note: If flu-like symptoms develop, take acetaminophen as advised by physician and take interferon at bedtime.
            						
         </li>
<li>
            							Note: Fertile, nonpregnant women need to use effective contraception.
            						
         </li>
<li>Use caution with hazardous activities until response to drug is known.</li>
<li>Learn about adverse effects and notify physician about those that cause significant discomfort.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>